PTPI

Petros Pharmaceuticals Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website etrospharma.com
Employees(FY) 24
ISIN US71678J2096

Performance

-15.93%

+17.24%

-21.54%

-28.11%

-79.12%

YTD

-78.35%

Profile

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Advanced Technical Analysis

Technical Analysis of PTPI 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PTPI

Stock Rank

Recent News & Updates

2024-12-18 20:15
Petros Pharmaceuticals Featured in 'New Era of Healthcare, AI, Data and Consumer Empowerment'(Accesswire)
2024-12-16 20:00
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually(Accesswire)
2024-10-19 05:28
Petros Pharmaceuticals Amends Presidents Employment Terms(Yahoo Finance)
2024-09-10 21:15
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)(Accesswire)
2024-09-02 21:00
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Accesswire)
2024-08-16 09:53
PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024(Investorplace)
2024-07-28 21:20
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)(Accesswire)
2024-07-15 21:00
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance(Accesswire)
2024-05-28 21:00
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch(Accesswire)
2024-05-20 21:15
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA(Accesswire)
2024-05-15 22:53
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-13 21:15
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe(Accesswire)
2024-05-13 19:00
Lemonaid Health Now Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals(Globenewswire)
2024-04-24 22:20
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health(Newsdirect)
2024-04-22 21:15
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health(Accesswire)
2024-04-15 21:15
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)(Accesswire)
2024-04-01 21:53
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-04-01 21:15
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status(Accesswire)
2024-03-18 21:00
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider(Accesswire)
2024-03-10 19:00
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc(Newsdirect)
2024-02-13 20:15
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider(Accesswire)
2024-01-23 20:15
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch(Accesswire)
2024-01-16 20:00
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch(Accesswire)
2023-12-11 21:00
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status(Accesswire)
2023-12-11 20:15
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestors (rosuvastatin) OTC Switch Technology Provider(Accesswire)
2023-12-04 20:15
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider(Accesswire)
2023-10-29 21:15
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)(Accesswire)
2023-10-18 21:00
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA(Accesswire)
2023-10-03 21:00
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label(Accesswire)
2023-09-27 20:00
Petros Pharmaceuticals to Present at the LD Micro Main Event XVI(Accesswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.